FrancophonIA/ELRC3.0 huggingface dataset:
English: Due to insufficient clinical data, the combination of elvitegravir with tipranavir is not recommended (see section 4.2).
Slovenian: Zaradi nezadostnih kliničnih podatkov kombinacija elvitegravirja s tipranavirjem ni priporočljiva (glejte poglavje 4.2).
English: The following pack size is available: outer cartons containing 1 bottle of 30 film-coated tablets.
Slovenian: Na voljo je naslednja velikost pakiranja: škatle z 1 plastenko s po 30 filmsko obloženimi tabletami.
English: However, clinical data have shown there are no clinically relevant changes in the exposure of methadone (which is primarily metabolised by CYP2B6 and CYP2C19) following co-administration with boosted elvitegravir versus administration of methadone alone (see Table 2).
Slovenian: Vendar pa so klinični podatki pokazali, da v izpostavljenosti metadonu (ki ga v glavnem presnavljata CYP2B6 in CYP2C19) ni klinično pomembnih sprememb, če se daje sočasno z ojačanim elvitegravirjem v primerjavi z dajanjem samega metadona (glejte preglednico 2).
English: The most common substitutions that emerged in HIV-1 isolates from elvitegravir-treated subjects were T66I/A (n = 8), E92Q/G (n = 7), T97A (n = 4), S147G (n = 4), Q148R (n = 4), and N155H (n = 5) in integrase.
Slovenian: Najpogostejše substitucije v integrazi, ki so se pojavile v izolatih HIV-1 oseb, zdravljenih z elvitegravirjem, so bile T66I/A (n = 8), E92Q/G (n = 7), T97A (n = 4), S147G (n = 4), Q148R (n = 4), in N155H (n = 5).
English: Elvitegravir is a modest inducer and may have the potential to induce CYP2C9 and/or inducible UGT enzymes.
Slovenian: Elvitegravir je zmeren induktor in lahko morda inducira encim CYP2C9 in/ali inducibilne encime UGT.
English: There is no specific antidote for overdose with elvitegravir.
Slovenian: Specifičnega antidota za preveliko odmerjanje elvitegravirja ni.
English: • If you notice within 18 hours of the time you usually take Vitekta, you must take the tablet as soon as possible.
Slovenian: • in to opazite v roku 18 ur od časa, ko zdravilo Vitekta običajno vzamete, morate tableto vzeti čim prej.
English: Uncommon suicidal ideation and suicide attempt (in patients with a pre-existing history of depression or psychiatric illness), depression, insomnia
Slovenian: samomorilne misli in poskus samomora (pri bolnikih z depresijo ali psihiatrično boleznijo v anamnezi), depresija, nespečnost
English: Elvitegravir is primarily metabolised and eliminated by the liver.
Slovenian: Elvitegravir v glavnem presnavljajo in izločajo jetra.
English: Excipient with known effect: Each tablet contains 6.2 mg lactose (as monohydrate).
Slovenian: Pomožne snovi z znanim učinkom: Ena tableta vsebuje 6,2 mg laktoze (v obliki laktoze monohidrata).
English: As elvitegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis.
Slovenian: Ker se elvitegravir močno veže na plazemske proteine, ni verjetno, da bi ga hemodializa ali peritonealna dializa odstranila v pomembni meri.
English: Elvitegravir-resistant viruses show varying degrees of cross-resistance to the integrase strand transfer inhibitor raltegravir depending on the type and number of substitutions.
Slovenian: Virusi, rezistentni na elvitegravir, kažejo različne stopnje navzkrižne rezistence na zaviralca prenosa zapisa integraze, raltegravir, odvisno od vrste in števila substitucij.
English: As didanosine is administered on an empty stomach, didanosine should be administered at least one hour before or two hours after Vitekta (which is administered with food).
Slovenian: Ker se didanozin daje na prazen želodec, je treba didanozin dati vsaj eno uro pred uporabo zdravila Vitekta (ki se daje s hrano) ali dve uri kasneje.
English: Animal studies do not indicate harmful effects of elvitegravir on fertility.
Slovenian: Študije na živalih ne kažejo škodljivih učinkov elvitegravirja na plodnost.
English: If you accidentally take more than the recommended dose of Vitekta you may be at increased risk of experiencing possible side effects with this medicine (see section 4 of this leaflet).
Slovenian: Če ste pomotoma zaužili odmerek zdravila Vitekta, višji od priporočenega, obstaja povečano tveganje za pojav možnih neželenih učinkov (glejte poglavje 4 tega navodila).
English: 0.8% (-17.7% to 19.3%)
Slovenian: 0,8 % (-17,7 % do 19,3 %)
English: What Vitekta looks like and contents of the pack
Slovenian: Izgled zdravila Vitekta in vsebina pakiranja
English: The recommended dose of Vitekta is one 85 mg tablet or one 150 mg tablet taken orally once daily with food.
Slovenian: Priporočeni odmerek zdravila Vitekta je ena 85 mg tableta ali ena 150 mg tableta peroralno enkrat na dan s hrano.
English: • if you are taking one of these medicines: carbamazepine, phenobarbital, phenytoin, used to treat epilepsy and prevent seizures rifampicin, used to prevent and treat tuberculosis and other infections St. John's wort (Hypericum perforatum), a herbal remedy used for depression and anxiety, or products that contain it
Slovenian: • Če jemljete katero od naslednjih zdravil: - karbamazepin, fenobarbital, fenitoin, uporabljajo se za zdravljenje epilepsije in preprečevanje epileptičnih napadov - rifampicin, uporablja se za preprečevanje in zdravljenje tuberkuloze in drugih okužb - šentjanževka (Hypericum perforatum), rastlinski pripravek, ki se uporablja za depresijo in tesnobo ali pripravki, ki jo vsebujejo
English: 4.7 Effects on ability to drive and use machines No studies on the effects of elvitegravir on the ability to drive and use machines have been performed.
Slovenian: 4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Študij o vplivu elvitegravirja na sposobnost vožnje in upravljanja s stroji niso izvedli.
English: Elvitegravir plasma concentrations are lower with antacids due to local complexation in the gastrointestinal tract and not to changes in gastric pH.
Slovenian: Koncentracije elvitegravirja v plazmi so z antacidi nižje zaradi lokalne kompleksacije v prebavilih in ne zaradi spremenjene vrednosti pH v želodcu.
English: Indigo carmine aluminium lake (E132), macrogol 3350 (E1521), polyvinyl alcohol (partially hydrolysed) (E1203), talc (E553B), titanium dioxide (E171), iron oxide yellow (E172).
Slovenian: Indigotin (E132), makrogol 3350 (E1521), polivinilalkohol (delno hidroliziran) (E1203), smukec (E553B), titanov dioksid (E171), rumeni železov oksid (E172).
English: If you are also taking didanosine, take it at least 1 hour before or at least 2 hours after Vitekta.
Slovenian: Če jemljete tudi didanozin, ga vzemite vsaj 1 uro pred uporabo zdravila Vitekta ali najmanj 2 uri po
English: Animal studies do not indicate direct or indirect harmful effects of elvitegravir with respect to reproductive toxicity.
Slovenian: Študije na živalih ne kažejo neposrednih ali posrednih škodljivih učinkov elvitegravirja na sposobnost razmnoževanja.
English: Virologic response was defined as achieving an undetectable viral load (HIV-1 RNA < 50 copies/mL).
Slovenian: Virološki odziv je bil opredeljen kot dosežena nezaznavna virusna obremenitev (HIV-1 RNA < 50 kopij/ml).
English: Mean steady-state exposure (AUCtau) of unboosted elvitegravir is ~ 20% lower after multiple dosing versus a single dose, indicating modest autoinduction of its metabolism.
Slovenian: Povprečna izpostavljenost (AUCtau) neokrepljenega elvitegravirja v stanju dinamičnega ravnovesja je ~ 20 % nižja po večkratnem odmerjanju v primerjavi z enim samim odmerkom, kar kaže na zmerno avtoindukcijo svoje presnove.
English: Autoimmune disorders (such as Graves' disease) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Slovenian: Poročajo o avtoimunskih boleznih (kot je Gravesova bolezen); čas do njihovega nastanka je spremenljiv, zato se lahko pojavijo tudi več mesecev po začetku zdravljenja (glejte poglavje 4.4).
English: The choice of dose of Vitekta depends on the co-administered protease inhibitor (see Table 1 and sections 4.4 and 4.5).
Slovenian: Izbira odmerka zdravila Vitekta je odvisna od sočasno uporabljenega zaviralca proteaze (glejte preglednico 1 in poglavji 4.4 in 4.5).
English: In addition, in vitro studies have shown that elvitegravir is a weak to modest inducer of CYP1A2, CYP2C19 and CYP3A enzymes.
Slovenian: Študije in vitro so poleg tega pokazale, da je elvitegravir šibek do zmeren induktor encimov CYP1A2, CYP2C19 in CYP3A.
English: Tell your doctor if you are lactose intolerant or intolerant to other sugars.
Slovenian: Obvestite zdravnika, če ne prenašate laktoze ali drugih sladkorjev.
English: It is unknown whether elvitegravir/metabolites are excreted in human milk.
Slovenian: Ni znano, ali se elvitegravir/presnovki izločajo v materino mleko.
English: Therefore, Vitekta should not be used during breastfeeding.
Slovenian: Zato se zdravilo Vitekta med dojenjem ne sme uporabljati.
English: Elvitegravir is primarily metabolised by CYP3A (see section 5.2).
Slovenian: Elvitegravir primarno presnavlja CYP3A (glejte poglavje 5.2).
English: In an in vitro chromosomal aberration test, elvitegravir was negative with metabolic activation; however, an equivocal response was observed without activation.
Slovenian: V testu kromosomske aberacije in vitro je bil elvitegravir negativen z aktivacijo presnove, vendar pa so brez aktivacije opazili
English: Croscarmellose sodium, hydroxypropyl cellulose, lactose (as monohydrate), magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate.
Slovenian: Premreženi natrijev karmelozat, hidroksipropilceluloza, laktoza (v obliki laktoze monohidrata), magnezijev stearat, mikrokristalna celuloza, natrijev lavrilsulfat.
English: Due to the need for co-administration of Vitekta with a ritonavir-boosted protease inhibitor, prescribers should consult the Summary of Product Characteristics of the co-administered protease inhibitor and ritonavir for a description of contraindicated medicinal products and other significant drug-drug interactions that may cause potentially life-threatening adverse reactions or loss of therapeutic effect and possible development of resistance.
Slovenian: Zaradi potrebe po sočasnem dajanju zdravila Vitekta z zaviralcem proteaze, ojačanim z ritonavirjem, morajo zdravniki, ki zdravilo predpisujejo, upoštevati povzetek glavnih značilnosti zdravila sočasno uporabljenega zaviralca proteaze in ritonavirja za opis kontraindiciranih zdravil in drugih pomembnih medsebojnih učinkov zdravil, ki lahko povzročijo potencialno življenjsko nevarne neželene učinke ali izgubo terapevtskega učinka in možen razvoj rezistence.
English: Metabolites produced by aromatic and aliphatic hydroxylation or glucuronidation are present in very low levels and do not contribute to the overall
Slovenian: Presnovki, nastali z aromatsko in alifatsko hidroksilacijo ali presnovki glukuronidacije so prisotni v zelo nizkih ravneh in ne prispevajo k splošni protivirusni aktivnosti
English: Uncommon dizziness, paraesthesia, somnolence, dysgeusia abdominal pain, diarrhoea, vomiting, nausea dyspepsia, abdominal distension, flatulence
Slovenian: omotica, parestezija, somnolenca, disgevzija bolečine v trebuhu, driska, bruhanje, navzea dispepsija, abdominalna distenzija, flatulenca
English: Co-administration of Vitekta with strong CYP3A inducers (including St. John's wort [Hypericum perforatum], rifampicin, carbamazepine, phenobarbital and phenytoin) is contraindicated (see sections 4.3 and 4.5).
Slovenian: Sočasna uporaba zdravila Vitekta z močnimi induktorji CYP3A (vključno s šentjanževko [Hypericum perforatum], rifampicinom, karbamazepinom, fenobarbitalom in fenitoinom) je kontraindicirana (glejte poglavji 4.3 in 4.5).
English: • carbamazepine, phenobarbital, phenytoin, used to treat epilepsy and prevent seizures
Slovenian: • karbamazepin, fenobarbital, fenitoin, uporabljajo se za zdravljenje epilepsije in preprečevanje epileptičnih napadov
English: Pack size: 1 bottle of 30 film-coated tablets.
Slovenian: Velikost pakiranja: 1 plastenka s 30 filmsko obloženimi tabletami.
English: suicidal ideation and suicide attempt (in patients with a pre-existing history of depression or psychiatric illness), depression, insomnia dizziness, paraesthesia, somnolence, dysgeusia abdominal pain, diarrhoea, vomiting, nausea dyspepsia, abdominal distension, flatulence
Slovenian: samomorilne misli in poskus samomora (pri bolnikih z depresijo ali psihiatrično boleznijo v anamnezi), depresija, nespečnost omotica, parestezija, somnolenca, disgevzija bolečine v trebuhu, driska, bruhanje, navzea dispepsija, abdominalna distenzija, flatulenca
English: The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of elvitegravir has not been studied.
Slovenian: Učinka hude jetrne okvare (stopnje C po Child-Pughu) na farmakokinetične lastnosti elvitegravirja niso proučevali.
English: • If you notice 18 hours or more after the time you usually take Vitekta, then do not take the missed dose.
Slovenian: • in to opazite po 18 urah ali več od časa, ko običajno vzamete zdravilo Vitekta, pozabljenega odmerka ne vzemite.
English: Upon boosting with ritonavir (100 mg), net inhibition of elvitegravir metabolism is observed with significantly increased systemic exposures (20-fold higher AUC), high trough concentrations, and longer median elimination half-life (9.5 versus 3.5 hours).
Slovenian: Po ojačanju z ritonavirjem (100 mg) so opazili neto zaviranje presnove elvitegravirja z močno povečano sistemsko izpostavljenostjo (20-krat višji AUC), visoke najnižje koncentracije in daljšo mediano razpolovnega časa izločanja (9,5 v primerjavi s 3,5 urami).
English: If the patient misses a dose of Vitekta within 18 hours of the time it is usually taken, the patient should take Vitekta with food as soon as possible and resume the normal dosing schedule.
Slovenian: Če bolnik izpusti odmerek zdravila Vitekta v roku 18 ur od časa, ko ga običajno vzame, naj bolnik vzame zdravilo Vitekta s hrano takoj, ko je mogoče, nato pa nadaljuje z običajnim režimom odmerjanja.
English: No studies on the effects of elvitegravir on the ability to drive and use machines have been performed.
Slovenian: Študij o vplivu elvitegravirja na sposobnost vožnje in upravljanja s stroji niso izvedli.
English: Relative to fasting conditions, the administration of boosted elvitegravir as the fixed-dose combination 150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/245 mg tenofovir disoproxil with a light meal (approximately 373 kcal, 20% fat) or high-fat meal (approximately 800 kcal, 50% fat) resulted in increased exposures of elvitegravir.
Slovenian: Relativno glede na pogoje na tešče je dajanje ojačanega elvitegravirja kot fiksne kombinacije 150 mg elvitegravir/150 mg kobicistat/200 mg emtricitabin/245 mg dizoproksiltenofovirat z lahkim obrokom (približno 373 kcal, 20 % maščobe) ali obrokom z visoko vsebnostjo maščobe (približno 800 kcal, 50 % maščobe) povzročilo povečanje izpostavljenosti elvitegravirju.
English: The Cmax and AUCtau of elvitegravir increased 22% and 36% with a light meal, while increasing 56% and 91% with a high-fat meal, respectively.
Slovenian: Za elvitegravir se je Cmax povečal za 22 % in AUCtau za 36 % pri lahkem obroku, pri obroku z visoko vsebnostjo maščobe pa za 56 % oz.
English: Co-administration of elvitegravir with oral contraceptives containing progestagens other than norgestimate has not been studied and therefore should be avoided.
Slovenian: Sočasne uporabe elvitegravirja s peroralnimi kontraceptivi, ki vsebujejo druge progestagene kot norgestimat, niso preučili, zato se ji je treba izogniti.
English: 1.6% (-33.0% to 36.2%)
Slovenian: 1,6 % (-33,0 % do 36,2 %)
English: In study GS-US-183-0145, diarrhoea was reported as an adverse reaction in 7.1% of subjects in the elvitegravir group and in 5.3% of subjects in the raltegravir group.
Slovenian: V študiji GS-US-183-0145 so o driski kot o neželenem učinku poročali pri 7,1 % oseb v skupini z elvitegravirjem in 5,3 % oseb v skupini z raltegravirjem.
English: When your supply of Vitekta starts to run low, get more from your doctor or pharmacist.
Slovenian: Ko se vaše zaloge zdravila Vitekta manjšajo, si ga priskrbite pri svojem zdravniku ali farmacevtu.
English: Recommendation concerning co-administration with ritonavir-boosted elvitegravir
Slovenian: Priporočilo glede sočasne uporabe z ritonavirjem ojačanega elvitegravirja
English: The prescriber should always refer to the Summary of Product Characteristics for ritonavir, or the protease inhibitor.
Slovenian: Zdravnik, ki zdravilo predpisuje, naj vedno gleda povzetek glavnih značilnosti zdravila za ritonavir ali za zaviralca proteaze.
English: In these combinations the dose is one 85 mg tablet each day, with food.
Slovenian: V teh kombinacijah je odmerek ena 85 mg tableta vsak dan, s hrano.
English: Vitekta 150 mg [Outer packaging only]
Slovenian: Vitekta 150 mg [samo na zunanji ovojnini]
English: Vitekta should be administered once daily as follows: - Either at the same time as a once daily ritonavir-boosted protease inhibitor - Or with the first dose of a twice daily ritonavir-boosted protease inhibitor.
Slovenian: Zdravilo Vitekta se daje enkrat na dan kot sledi: - bodisi sočasno z zaviralcem proteaze, ojačanim z ritonavirjem, ki se daje enkrat na dan, - ali s prvim odmerkom zaviralca proteaze, ojačanega z ritonavirjem, ki se daje dvakrat na dan
English: In these combinations the dose is one 150 mg tablet each day, with food.
Slovenian: V teh kombinacijah je odmerek ena 150 mg tableta vsak dan, s hrano.
English: If the patient vomits within 1 hour of taking Vitekta another tablet should be taken.
Slovenian: Če bolnik v roku 1 ure od jemanja zdravila Vitekta bruha, naj vzame drugo tableto.
English: Co-administration of elvitegravir and rilpivirine is not expected to change elvitegravir plasma concentrations, therefore no dose adjustment of Vitekta is required.
Slovenian: Ne pričakuje se, da bi sočasno dajanje elvitegravirja in rilpivirina spremenilo koncentracije elvitegravirja v plazmi, zato prilagoditev odmerka zdravila Vitekta ni potrebna.
English: Following oral administration of ritonavir-boosted [
Slovenian: Po peroralni uporabi z ritonavirjem ojačanega [
English: Adverse reactions to elvitegravir from clinical study experience are listed in Table 3 below, by body system organ class and frequency.
Slovenian: Povzetek neželenih učinkov, prikazan v preglednici Neželeni učinki elvitegravirja iz izkušenj v klinični študiji so našteti v spodnji preglednici 3 po organskih sistemih in pogostnosti.
English: Elvitegravir was non-inferior in achieving HIV-1 RNA < 50 copies/mL when compared to raltegravir.
Slovenian: Elvitegravir je bil enakovreden pri doseganju HIV-1 RNA < 50 kopij/ml v primerjavi z raltegravirjem.
English: Interaction not studied with elvitegravir.
Slovenian: Interakcij z elvitegravirjem niso preučili.
English: In study GS-US-183-0145, patients were randomised in a 1:1 ratio to receive either elvitegravir (150 mg or 85 mg) once daily or raltegravir 400 mg twice daily, each administered with a background regimen (BR) containing a fully-active ritonavir-boosted protease inhibitor (either atazanavir, darunavir, fosamprenavir, lopinavir or tipranavir) and a second agent.
Slovenian: V študiji GS-US-183-0145 so bili bolniki randomizirani v razmerju 1:1 za prejemanje elvitegravirja (150 mg ali 85 mg) enkrat dnevno ali raltegravirja 400 mg dvakrat dnevno, oboje z osnovnim režimom, ki je vseboval polno aktivni zaviralec proteaze, ojačan z ritonavirjem (bodisi atazanavir, darunavir, fosamprenavir, lopinavir ali tipranavir) in še drugo zdravilo.
English: No dose adjustment of Vitekta is required for patients with renal impairment (see section 5.2).
Slovenian: Prilagajanje odmerka zdravila Vitekta za bolnike z ledvično okvaro ni potrebno (glejte poglavje 5.2).
English: Following oral administration of ritonavir-boosted elvitegravir with food in HIV-1 infected subjects, elvitegravir peak plasma concentrations were observed 4 hours post-dose.
Slovenian: Po peroralnem dajanju z ritonavirjem ojačanega elvitegravirja s hrano osebam, okuženim z virusom HIV-1, so najvišje plazemske koncentracije elvitegravirja opazili 4 ure po odmerku.
English: The maximum doses of elvitegravir tested in the development toxicity studies in rats and rabbits corresponded to exposures that are approximately 29-fold and 0.2-fold the human therapeutic exposure, respectively.
Slovenian: Največji odmerek elvitegravirja, ki so ga preizkusili v študijah vpliva na sposobnost razvoja pri podganah in kuncih, je ustrezal približno 29-kratni oziroma 0,2-kratni terapevtski izpostavljenosti pri ljudeh.
English: Excipient with known effect: Each tablet contains 10.9 mg lactose (as monohydrate).
Slovenian: Pomožne snovi z znanim učinkom: Ena tableta vsebuje 10,9 mg laktoze (v obliki laktoze
English: For example, atazanavir/ritonavir and lopinavir/ritonavir (potent UGT1A1/3 inhibitors) have been shown to significantly increase the plasma concentrations of elvitegravir (see Table 2).
Slovenian: Pokazalo se je na primer, da atazanavir/ritonavir in lopinavir/ritonavir (močni zaviralci UGT1A1/3) močno povečajo koncentracije elvitegravirja v plazmi (glejte preglednico 2).
English: Boosting elvitegravir with an agent other than ritonavir may result in suboptimal plasma concentrations of elvitegravir and/or the protease inhibitor leading to loss of therapeutic effect and possible development
Slovenian: Ojačitev elvitegravirja z drugim zdravilom kot ritonavirjem lahko povzroči suboptimalne koncentracije elvitegravirja in/ali zaviralca proteaze v plazmi, kar lahko povzroči izgubo terapevtskega učinka in možen razvoj rezistence.
English: • St. John's wort (Hypericum perforatum), a herbal remedy used for depression and anxiety, or products that contain it
Slovenian: • šentjanževka (Hypericum perforatum), rastlinski pripravek, ki se uporablja za depresijo in tesnobo) ali pripravki, ki jo vsebujejo
English: The use of Vitekta with HIV-1 protease inhibitors or dosing frequencies other than those presented in Table 1 may result in inadequate or elevated plasma levels of elvitegravir and/or the co-administered medicinal products.
Slovenian: Uporaba zdravila Vitekta z zaviralci proteaze HIV-1 ali pogostnostmi odmerjanja, razen s tistimi, predstavljenimi v preglednici 1, lahko povzroči nezadostno ali povečano raven elvitegravirja in/ali sočasno uporabljenih zdravil v plazmi.
English: Medicines that should never be taken with Vitekta:
Slovenian: Nekaterih zdravil ne smete nikoli uporabljati skupaj z zdravilom Vitekta:
English: Common headache
Slovenian: glavobol
English: Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
English: AUC: ↑ 186% Cmax: ↑ 115% Cmin: ↑ 323%
Slovenian: maravirok:§ AUC: ↑ 186 % Cmax: ↑ 115 % Cmin: ↑ 323 %
English: Your treatment with Vitekta should only be started by a doctor who is experienced in treating
Slovenian: Vaše zdravljenje z zdravilom Vitekta sme uvesti le zdravnik z izkušnjami v zdravljenju okužbe z
English: Patients should be advised to seek medical advice if they experience joint aches and pain, joint
Slovenian: Bolnikom je treba svetovati, naj poiščejo zdravniško pomoč, če se jim pojavijo bolečine v sklepih, togost sklepov ali težave z
English: In study GS-US-183-0145, subgroup analyses by co-administered protease inhibitor showed similar rates of virologic success for elvitegravir and raltegravir within each protease inhibitor subgroup at weeks 48 and 96 (HIV-1 RNA < 50 copies/mL) (Table 6).
Slovenian: V študiji GS-US-183-0145 so analize podskupin sočasno uporabljenega zaviralca proteaze pokazale podobne stopnje virološkega uspeha za elvitegravir in raltegravir znotraj vsake podskupine zaviralcev proteaze v 48. in 96. tednu (HIV-1 RNA < 50 kopij/ml) (preglednica 6).
English: Elvitegravir is primarily metabolised by CYP3A.
Slovenian: Elvitegravir primarno presnavlja CYP3A.